JPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

JPMorgan Chase & Co. boosted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 1,171.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 371,758 shares of the company’s stock after purchasing an additional 342,516 shares during the quarter. JPMorgan Chase & Co. owned about 0.54% of EyePoint Pharmaceuticals worth $2,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Franklin Resources Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. Geode Capital Management LLC lifted its position in EyePoint Pharmaceuticals by 16.1% during the third quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock valued at $9,583,000 after purchasing an additional 166,699 shares during the last quarter. Barclays PLC grew its stake in EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after buying an additional 197,033 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of EyePoint Pharmaceuticals by 59.4% in the 3rd quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock worth $1,372,000 after buying an additional 64,008 shares during the last quarter. Finally, Patient Square Capital LP purchased a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at $10,882,000. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Up 2.9 %

NASDAQ:EYPT opened at $7.48 on Monday. The firm has a market capitalization of $510.52 million, a P/E ratio of -3.74 and a beta of 1.49. The company has a fifty day moving average of $8.40 and a 200 day moving average of $8.96. EyePoint Pharmaceuticals, Inc. has a 52 week low of $6.90 and a 52 week high of $30.99.

Analysts Set New Price Targets

EYPT has been the subject of several research reports. Chardan Capital upped their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Citigroup started coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective for the company. Scotiabank began coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective on the stock. Robert W. Baird cut their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.